A study of the combination of indinavir, ritonavir, enteric-coated ddI [didanosine] and d4T [stavudine] in nucleoside and non-nucleoside reverse transcriptase inhibitor experienced patients: an open-label study investigating differences between women and men
Latest Information Update: 21 Oct 2005
Price :
$35 *
At a glance
- Drugs Didanosine (Primary) ; Indinavir (Primary) ; Ritonavir (Primary) ; Stavudine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 21 Oct 2005 New trial record.